02 Jun 2022 | 02:45 PM GMT

Pharma - DTx: What Does Success Look Like?

About this Meeting

In theory, Digital Therapeutics (DTx) and pharma are natural bedfellows, with both looking for commercially viable ways to connect with patients and improve outcomes. In practice, we are still in the early days of this marriage and have yet to nail down the best business model for DTx in pharma companies. Despite the increasing number of partnerships, it is still hard to define what success looks like for both parties. This meeting will examine how to build fruitful partnerships for both sides. Join HealthXL in this session as we break down the following key questions:  

  • What partnership models have worked well and how can they be replicated?  
  • How can pharma and DTx companies ensure they have a transparent, two-way conversation while managing commercial sensitivities?  
  • What do DTx companies look for in a pharma partner? How can they better understand the specific company they want to work with, the internal stakeholders, their needs, and their roadmap? 
  • What are pharma companies looking at when choosing a DTx company? How can they analyze the team and the project? At what stage of maturity - in terms of regulatory approvals, commercial readiness, cross-functional experience - should they get involved? How can pharma manage its internal innovation teams to harness partnerships?